Botryocladia leptopoda is a red macroalga known for its bioactive compounds with antioxidant, anti-inflammatory, and skin-regenerative properties. The study aimed to examine their effects on UV protection, collagen synthesis, fibroblast proliferation, and pigmentation modulation. Bioactive compounds were extracted using two solvents, producing ethanol extract (FE) and alkaline extracts (AE). Methods involved characterizing extracts using mass spectrometry and assessing their effects on human fibroblasts under UVB-induced damage. UV absorbance, ROS production, and collagen synthesis were evaluated. The FE extract, which comprised 4-hydroxyquinoline, phytosphingosine, and docosapentaenoic acid, reinstated procollagen type I synthesis to 113% of baseline levels and reduced TGF-β1-mediated fibroblast proliferation to 87.78%. FE also suppressed Smad2 and α-SMA by 71% and 68%, respectively, indicating modulation of fibrosis-associated pathways. AE, containing 4-hydroxyquinoline and phenylalanine betaine, demonstrated dose-responsive cellular repair, reducing fibroblast proliferation to 97.86% and collagen Type I expression by 73% at 1000 μg/mL. Both extracts decreased ROS production, with FE and AE reducing levels by 21.4% and 19.7%, respectively, under UVB-induced oxidative stress. FE showed superior scar inhibition, while AE excelled in skin regeneration and pigmentation management.

Background: Sustainable, dual-action ergogenic strategies are underexplored; most products target a single pathway and rarely upcycle seafood sidestreams. We therefore tested an upcycled formulation combining grouper bone hydrolysate and Undaria pinnatifida extract (GU) for ergogenic and microbiota effects in mice. We tested the ergogenic and microbiota modulating effects of GU in mice versus a vehicle and a BCAA control. Methods: GU was prepared via enzymatic hydrolysis of marine by-products and administered to male ICR mice for 4 weeks. Mice were divided into five groups (n = 7/group), receiving a vehicle control, a branched-chain amino acid (BCAA) supplement, or GU at three dose levels (1X, 2X, 3X) based on human-equivalent conversion. Exercise performance was assessed via grip strength and treadmill tests. Biochemical markers of fatigue, body composition, and safety indicators were also analyzed. Gut microbiota was evaluated using 16S rRNA sequencing and constrained principal coordinates analysis (CPCoA). Results: Four weeks of GU supplementation significantly enhanced exercise performance [(treadmill time ↑ Δ = 10.2–11.7 min versus vehicle (q ≤ 0.0002), grip strength ↑ Δ = 40.4–48.5 g (q ≤ 0.05)] and lean body mass [FFM ↑ at GU-1X (Δ = +0.80%, q = 0.0123)], surpassing the commercial BCAA control. Biochemical analyses indicated reduced exercise-induced lactate accumulation [(post-exercise lactate ↓ Δ = −2.71/−2.18 mmol·L⁻¹, q = 0.0006)]. Gut microbiota profiling revealed distinct shifts in community composition in GU-treated groups, notably with an increased abundance of beneficial taxa such as Lactobacillus and Muribaculum. These alterations reflect the prebiotic activity of seaweed-derived polysaccharides, promoting a healthier gut microbial profile. Notably, GU improved metabolic markers (aspartate aminotransferase, [AST]; lactate dehydrogenase, [LDH]) without inducing toxicity. Conclusions: These findings indicate that GU functions as a dual-action supplement, coupling amino acid-mediated muscle anabolism with microbiome modulation to enhance physical performance and metabolic health. As an upcycled marine product, it presents a sustainable and effective strategy for exercise support. Future studies should include 90-day safety, mechanistic assays, and a preregistered human pilot.

Muscle atrophy, whether associated with aging, chronic disease, or glucocorticoid treatment, remains a significant clinical challenge with few effective therapeutic options. This study investigated the protective effects of fucoidan from Undaria pinnatifida and peptides derived from the hybrid grouper (Epinephelus fuscoguttatus × Epinephelus lanceolatus) against dexamethasone (DEX)-induced muscle atrophy in vitro and in vivo. In C2C12 myotubes, DEX suppressed anabolic signaling (mTOR, p-Akt, PI3K, p-S6K1, TRPV4) and upregulated catabolic mediators (FOXO3, MuRF1, Atrogin-1, Cathepsin L, REDD2). Fucoidan mainly suppressed catabolic signaling, peptides enhanced anabolic pathways, and their combination synergistically restored protein turnover. In a DEX-induced mouse model, the combined treatment significantly preserved muscle weight, improved strength and endurance, and protected myofiber morphology, exceeding the effects of either treatment alone or leucine. Compositional profiling confirmed that fucoidan was enriched in fucose and sulfate, whereas grouper peptides were abundant in branched-chain amino acids and bioactive dipeptides, supporting their complementary mechanisms. These findings demonstrate that fucoidan and grouper-derived peptides exert distinct yet synergistic effects on muscle protein homeostasis, highlighting their translational potential as safe, mechanism-based interventions for preventing and treating muscle-wasting conditions such as sarcopenia, cachexia, and glucocorticoid-induced atrophy.

Wound healing is a complex process involving coordinated actions of multiple cell types. Therefore, when developing therapeutics to promote wound healing, it is essential to consider the synergistic contributions of various cells at different stages of the healing process. In this study, we evaluated the potential of different extracts of Botryocladia leptopoda as wound-healing agents by examining their effects on antioxidant activity, cytotoxicity, cell migration, anti-inflammatory properties, and expressions of specific biomarkers associated with wound healing. Results indicated that the ethanol extract (FE) and hexane extract (HE) exhibited the highest DPPH radical scavenging activity, reaching up to 94%. The alkaline extract (AE) showed the strongest antioxidant ability in the FICA assay, with a maximum of 99%. In addition, the FE and AE provided anti-inflammatory actions that inhibited tumor necrosis factor (TNF)-α and interleukin (IL)-6 in lipopolysaccharide (LPS)-treated RAW 264.7 cells. Further analyses suggested that the FE and AE enhanced cell proliferation (210% and 112%) and migration (442.2% and 535.6%) and regulated wound healing-related genes, including matrix metalloproteinase 2, MMP9, and tissue inhibitor of metalloproteinase 2 (TIMP2) to avoid scar formation and accelerate wound healing. Lastly, the identification of potential compounds within the extract using the UHPLC system further supports its prospective medical applications. Taken together, these findings indicated that the FE and AE from B. leptopoda exhibited remarkable in vitro wound-healing properties, highlighting their potential for applications in pharmaceutical industries and health food development.

Wound healing is a complex process involving coordinated actions of multiple cell types. Therefore, when developing therapeutics to promote wound healing, it is essential to consider the synergistic contributions of various cells at different stages of the healing process. In this study, we evaluated the potential of different extracts of Botryocladia leptopoda as wound-healing agents by examining their effects on antioxidant activity, cytotoxicity, cell migration, anti-inflammatory properties, and expressions of specific biomarkers associated with wound healing. Results indicated that the ethanol extract (FE) and alkaline extract (AE) showed great antioxidation abilities against DPPH and FICA. In addition, the FE and AE provided anti-inflammatory actions that inhibited tumor necrosis factor (TNF)-α and interleukin (IL)-6 in lipopolysaccharide (LPS)-treated RAW 264.7 cells. Further analyses suggested that the FE and AE enhanced cell proliferation and migration, and regulated would healing-related genes including matrix metalloproteinase 1 (MMP1), MMP2, MMP9, and tissue inhibitor of metalloproteinase 2 (TIMP2) to avoid scar formation and accelerate wound healing. Taken together, these findings indicated that the FE and AE from B. leptopoda exhibited remarkable in vitro wound-healing properties, highlighting their potential for applications in pharmaceutical industries and health food development.